NBP

0.83005.66%
CS

Charles Silberstein

Chief Financial Officer

Dr. Charles Silberstein, also known as Chuck, MD, CFA, MBA, has been Chief Financial Officer of NovaBridge Biosciences Inc. since November 2, 2026. He is a Co-Founder and Chief Executive Officer of FytonBio, Inc. Mr. Silberstein had been Chief Financial Officer and Head of Business Development of Applied Therapeutics, Inc., since May 26, 2020 until January 28, 2022. He had been Chief Financial Officer at GentiBio, Inc. since February 2022 until 2024. From 2018 to 2020, Dr. Silberstein served as Senior Vice President, R&D Strategic Execution and Alignment and Senior Vice President, Business Development, at Allergan (NYSE: AGN). From 2015 to 2018, he was Executive Director and Senior Healthcare Analyst at J.P. Morgan Asset Management, covering the large-cap U.S. biopharmaceutical sector. He was a Vice President and Portfolio Manager at The Boston Company Asset Management, LLC. Dr. Silberstein was also a member of the core research team covering the health care sector. from 2000 to 2005, he served as Vice President at Goldman Sachs Asset Management, covering the U.S. healthcare sector. Dr. Silberstein had been with Goldman Sachs since January 2006. Before that, he served as a Portfolio Manager at The Dreyfus Corporation. Prior thereto, he served as a Portfolio Manager of Goldman Sachs for its mid-cap growth products and an Analyst covering health care stocks from 2000 to 2006. Dr. Silberstein received his MBA from Columbia Business School in 2000 and his MD, with distinction in research in developmental neurobiology, from Albert Einstein College of Medicine in 1995. He earned a BS in Biology from Yeshiva University in 1995 and is a CFA charterholder.

公司職務